Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Published Date: 24 Jun 2024

No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Food insecurity linked to tumor growth in pediatric neuroblastoma

2.

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.

3.

Predicting adult mortality from oral cancer using a machine learning approach.

4.

Preoperative Embolization Linked to Relapse-Free Survival in Meningioma

5.

Many patients learn they could have cancer in the emergency department


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot